Differentiated thyroid cancer: management of patients with radioiodine nonresponsive disease.
Reads0
Chats0
TLDR
This paper will focus on the management and treatment of metastatic differentiated thyroid cancers that do not take up radioactive iodine.Abstract:
Differentiated thyroid carcinoma (papillary and follicular) has a favorable prognosis with an 85% 10-year survival. The patients that recur often require surgery and further radioactive iodine to render them disease-free. Five percent of thyroid cancer patients, however, will eventually succumb to their disease. Metastatic thyroid cancer is treated with radioactive iodine if the metastases are radioiodine avid. Cytotoxic chemotherapies for advanced or metastatic noniodine avid thyroid cancers show no prolonged responses and in general have fallen out of favor. Novel targeted therapies have recently been discovered that have given rise to clinical trials for thyroid cancer. Newer aberrations in molecular pathways and oncogenic mutations in thyroid cancer together with the role of angiogenesis in tumor growth have been central to these discoveries. This paper will focus on the management and treatment of metastatic differentiated thyroid cancers that do not take up radioactive iodine.read more
Citations
More filters
Journal ArticleDOI
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger,Makoto Tahara,Lori J. Wirth,Bruce G. Robinson,Marcia S. Brose,Rossella Elisei,Mouhammed Amir Habra,Kate Newbold,Manisha H. Shah,Ana O. Hoff,Andrew G. Gianoukakis,Naomi Kiyota,Matthew H. Taylor,Sung Bae Kim,Monika K. Krzyzanowska,Corina E. Dutcus,B.D.L. Heras,J. Zhu,Steven I. Sherman +18 more
TL;DR: Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer.
Journal ArticleDOI
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose,Christopher M. Nutting,Barbara Jarzab,Rossella Elisei,Salvatore Siena,Lars Bastholt,Christelle De La Fouchardiere,Furio Pacini,Ralf Paschke,Young Kee Shong,Steven I. Sherman,Johannes W. A. Smit,John Chung,Christian Kappeler,Carol Peña,Istvan Molnar,Martin Schlumberger +16 more
TL;DR: It is suggested that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer and progression-free survival significantly improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status.
Journal ArticleDOI
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)
Rajesh V. Thakker,Paul J. Newey,Gerard V Walls,John P. Bilezikian,Henning Dralle,Peter R. Ebeling,Shlomo Melmed,Akihiro Sakurai,Francesco Tonelli,Maria Luisa Brandi +9 more
TL;DR: It is recommended that MEN1 patients and their families should be cared for by multidisciplinary teams comprising relevant specialists with experience in the diagnosis and treatment of patients with endocrine tumors.
Journal ArticleDOI
Progress in molecular-based management of differentiated thyroid cancer
TL;DR: Novel molecular-targeted treatments hold great promise for radioiodine-refractory and surgically inoperable thyroid cancers as shown in clinical trials and are likely to become a component of the standard treatment regimen for patients with thyroid cancer in the near future.
Journal ArticleDOI
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama,Junji Matsui,Kotaro Kodama,Naoko Hata-Sugi,Takayuki Kimura,Kiyoshi Okamoto,Yukinori Minoshima,Masao Iwata,Yasuhiro Funahashi +8 more
TL;DR: Data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
References
More filters
Journal ArticleDOI
Cancer Statistics, 2009
TL;DR: The most recent data on cancer incidence, mortality, and survival from the American Cancer Society (ACS) is presented in this paper, where the authors compare the three major cancer sites in men (lung, prostate, and colon and rectum [colorectum]) and in two major cancers sites in women (breast and colorectal) over a 15-year period.
Journal ArticleDOI
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
David S. Cooper,Gerard M. Doherty,Bryan R. Haugen,Richard T. Kloos,Stephanie L. Lee,Susan J. Mandel,Ernest L. Mazzaferri,Bryan McIver,Furio Pacini,Martin Schlumberger,Steven I. Sherman,David L. Steward,R. Michael Tuttle +12 more
TL;DR: Evidence-based recommendations in response to the appointment as an independent task force by the American Thyroid Association to assist in the clinical management of patients with thyroid nodules and differentiated thyroid cancer represent, in the authors' opinion, contemporary optimal care for patients with these disorders.
Journal ArticleDOI
Mechanisms of angiogenesis and arteriogenesis.
TL;DR: The cellular and molecular mechanisms underlying the formation of endothelium-lined channels and their maturation via recruitment of smooth muscle cells (arteriogenesis) during physiological and pathological conditions are summarized, alongside with possible therapeutic applications.
Journal ArticleDOI
Inhibition of mutated, activated BRAF in metastatic melanoma.
Keith T. Flaherty,Igor Puzanov,Kevin B. Kim,Antoni Ribas,Grant A. McArthur,Jeffrey A. Sosman,Peter J. O'Dwyer,Richard J. Lee,Joseph F. Grippo,K. B. Nolop,Paul B. Chapman +10 more
TL;DR: Treatment of metastatic melanoma with PLX4032 in patients with tumors that carry the V600E BRAF mutation resulted in complete or partial tumor regression in the majority of patients.
Related Papers (5)
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger,Makoto Tahara,Lori J. Wirth,Bruce G. Robinson,Marcia S. Brose,Rossella Elisei,Mouhammed Amir Habra,Kate Newbold,Manisha H. Shah,Ana O. Hoff,Andrew G. Gianoukakis,Naomi Kiyota,Matthew H. Taylor,Sung Bae Kim,Monika K. Krzyzanowska,Corina E. Dutcus,B.D.L. Heras,J. Zhu,Steven I. Sherman +18 more